Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Regeneron Pharmaceuticals, Inc. REGN obtained FDA approval for linvoseltamab-gcpt for the treatment of relapsed or refractory (R/R) multiple myeloma (MM). The regulatory body granted accelerated ...

Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines Provided by GlobeNewswire Apr 22, 2025 3:00am ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...

At the time, GSK made a $300 million equity investment in 23andMe, which is more than the amount Regeneron could end up paying for the entire company.

Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results ...

Regeneron Pharma Partners With FujiFilm Diosynth To Boost Capacity At $3 Bln Investment April 22, 2025 — 07:38 am EDT Written by RTTNews.com for RTTNews -> ...

The results fell short of Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $8.43 per share.

Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness ...

Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth, potentially doubling its U.S. manufacturing capacity and ...

Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines Apr. 22, 2025 6:00 AM ET Regeneron Pharmaceuticals, Inc. (REGN) ...